Economic Perspectives on Personalized Health Care and Prevention

Abstract

The objective of this paper is to provide an overview of economic evaluation of personalized medicine, focusing particularly on the use of costeffectiveness analysis and other methods of valuation. We draw on insights from the literature and our work at the University of California, San Francisco Center for Translational and Policy Research on Personalized Medicine (TRANSPERS). We begin with a discussion of why personalized medicine is of interest and challenges to adoption, whether personalized medicine is different enough to require different evaluation approaches, and what is known about the economics of personalized medicine. We then discuss insights from TRANSPERS research and six areas for future research:1.

The economic value of personalized medicine tests: what we know and what we need to know

“…Thus, our research group is developing approaches to assessing the value of these new technologies given the complexities they raise, such as the results they may provide on conditions that are not treatable (http://pharmacy.ucsf.edu/news/2013/03/11/1/). 25 Our work has shown that stakeholders, such as health payers, want a broad range of information on new technologies in order to promote informed coverage decisions. 36 …”

“…Future research should also consider examining other approaches to measuring values, which have not to date been used widely to examine personalized medicine, such as budget-impact analysis, value-of-information analysis, stated choice, and willingness-to-pay methods. 24,25 …”

“…Future studies should examine reasons for differences in cost-effectiveness and the impact of heterogeneity. 25,26 …”

Economic evaluations of personalized medicine: existing challenges and current developments

“…Several recent reviews have explored different aspects of the challenges affecting the evaluation of pharmacogenetics. Phillips et al 14 presented a detailed overview of various aspects relating to economic evaluations of personalized medicine, and highlighted six areas for future research, ranging from applying existing methods to assessments of personalized medicine to developments of new conceptual frameworks and methods specific to these technologies. Godman et al 15 discussed current knowledge of the value of personalized medicine and concerns relating to personalized medicine from a payer’s perspective.…”

Personalized Medicine as an Updated Model of National Health-Care System. Part 2. Towards Public and Private Partnerships

“…Данный показатель является необходимым звеном в оценке функционирования системы здравоохране-ния в целом, отдельных ее подразделений и структур, а также экономическим обоснованием мероприятий по охране здоровья населения [11][12][13][14].…”